TY - JOUR T1 - ▼ Daclizumab withdrawn from the market worldwide JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull DO - 10.1136/dtb.2018.4.0604 SP - dtb604 A2 - , Y1 - 2018/03/08 UR - http://dtb.bmj.com/content/early/2018/03/08/dtb.2018.4.0604.1.abstract N2 - Biogen and AbbVie have announced the voluntary worldwide withdrawal of marketing authorisations for daclizumab (Zinbryta) for the treatment of relapsing multiple sclerosis (MS) as a result of the “complex and evolving benefit/risk profile” of the drug.1 Following seven reported cases of inflammatory brain disorders (encephalitis and meningoencephalitis) associated with daclizumab, the European Medicines Agency (EMA) began an urgent review of the safety of the drug.2Clinicians will be contacted directly with further information about the withdrawal of daclizumab. … ER -